Latest news with #VyomeHoldings
Time of India
a day ago
- Business
- Time of India
Vyome Holdings lists as Hind on Nasdaq
Vyome Holdings BENGALURU: Vyome Holdings, created through the merger of biotech startup Vyome Therapeutics and Nasdaq-listed ReShape Lifesciences, began trading on Friday under the ticker 'Hind', with Vyome shareholders holding a controlling 91.6% stake in the combined company. The debut coincided with India's 79th Independence Day. Stay informed with the latest business news, updates on bank holidays , public holidays , current gold rate and silver price .
Yahoo
a day ago
- Business
- Yahoo
Vyome to leverage US-India ties to tackle $100B immuno-inflammatory market
-- U.S.-India focused clinical-stage pharmaceutical maker Vyome Holdings (Nasdaq: HIND) rang the opening bell at the NASDAQ on Friday, celebrating Indian Independence Day and its trading debut after a reverse merger with ReShape Lifesciences. Shares of HIND last traded at $13.15, down 16%. The company is targeting the immuno-inflammatory market in the US and globally, valued at $100 billion. "The HIND journey begins today, a journey in which anyone, anywhere in the world can now participate thanks to our stock being on Nasdaq," said Krishna Gupta, Chairman of Vyome. Co-founder Shiladitya Sengupta, who also serves as Associate Professor of Medicine at Harvard Medical School, pointed to the company's "very deep" innovation pipeline and access to talent in both the United States and India. On how the US-India tech and innovation pipeline positions the company for growth, Gupta exclusively told 'The company has a pipeline of clinical stage assets; for each, Vyome has a plan to unlock value over the next 12-24 months. The research is being done collaboratively across India and the US.' The company decided to go public via a reverse merger versus the traditional route because they 'felt like it would be an easier and more efficient path if we could find a very clean public shell, which we did,' Gupta added. 'We were confident that opening up access to our vision to the entire world was the way we wanted to build the company going forward.' The Chairman doesn't feel the recently strained U.S./India relationship related to tariffs and Russian oil will have a negative impact on the company. 'It hasn't, nor do we think the relationship will be strained much longer - it's crazy to think that may be a contrarian view at this specific moment,' Gupta said in response to a question about whether the strained U.S./India relationship impacts the company. 'This is the defining partnership of the times, and the US and India will remain friends and collaborators, particularly in innovation-related endeavors.' Related articles Vyome to leverage US-India ties to tackle $100B immuno-inflammatory market Opendoor stock jumps after CEO exit, retail activists claim win The race for sovereign AI is intensifying. Here's what you need to know Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
